Sutro Biopharma, Inc. (STRO)

In the past six months, Sutro Biopharma's stock experienced several notable events. In August 2025, Sutro reported its second-quarter financial results and Ipsen decided not to advance the STRO-003 program. In September 2025, the company announced an organizational restructuring. In November 2025, Sutro reported its third-quarter financial results and announced FDA clearance for STRO-004. In December 2025, Sutro announced a 1-for-10 reverse stock split and the first cohort of patients was dosed in the Phase 1 trial of STRO-004. In January 2026, Sutro Biopharma's shares surged following an analyst upgrade. In February 2026, the stock price has been rising due to positive investor sentiment. The stock's 52-week range has been between $5.23 and $21.25, and the share price declined by 22.14% from January 31, 2025, to January 30, 2026.

Sutro Biopharma's products and services do not exhibit typical consumer demand seasonality. The demand for its product candidates is driven by clinical trial progress, regulatory approvals, and the medical need for new treatments, rather than seasonal consumer patterns.

Sutro Biopharma, Inc. is a clinical-stage company focused on biopharmaceutical products for cancer and autoimmune disorders. They utilize their XpressCF and XpressCF+ platforms to develop protein therapeutics, including antibody-drug conjugates (ADCs), bispecific antibodies, cytokine-based immuno-oncology therapies, and vaccines. Key product candidates include STRO-001, STRO-004, STRO-006 and STRO-227. STRO-002 was deprioritized and STRO-003 was not advanced by Ipsen. Sutro Biopharma has collaboration and license agreements with companies such as Merck, Celgene Corporation, EMD Serono, and Astellas Pharma Inc.

Sutro Biopharma, Inc. is headquartered in South San Francisco, California, United States. It has a broader geographic reach through partnerships with international pharmaceutical companies.

Sutro Biopharma has received past recognitions such as BioSpace “Best Places to Work,” World ADC “Best New Drug Developer,” and FierceBiotech “Fierce 15” Biotech Companies. However, restructurings, layoffs, and the deprioritization of STRO-003 have likely impacted its reputation negatively. Positive developments such as the FDA clearance of the IND for STRO-004 and analyst upgrades have contributed to a more positive outlook.

Sutro Biopharma, Inc. has a significant number of institutional owners and shareholders. Some of the largest institutional shareholders include Vanguard Group Inc and UBS Group AG. Insider ownership was reported at -0.01%.